Phantomics wins Taiwanese approval for noninvasive cardiomyopathy diagnostic solution

Phantomics, a Korean healthcare AI startup,  said Tuesday that it has received marketing authorization from the Taiwan Food and Drug Administration (TFDA) for Myomics, a noninvasive cardiomyopathy diagnostic solution.

With this authorization, Phantomics will begin marketing Myomics in Taiwan.

Phantomics is an imaging diagnostic solution startup founded by Professor Choi Byoung-wook of the Department of Radiology at Severance Hospital. It aims to provide fast and accurate diagnostic results using noninvasive diagnostic technologies, including magnetic resonance imaging (MRI) and computed tomography (CT).

Earlier the year, the company received the CES Innovation Award, the first in the Korean medical imaging AI industry, in recognition of its high technology and innovation.

Myomics, which recently received Taiwan’s medical device license, is a medical AI solution launched by Phantomics in 2020, which non-invasively extracts dozens of imaging biomarkers from cardiac MRIs to diagnose myocardial diseases, including heart failure, myocarditis, and amyloidosis. It has already won marketing authorization from the U.S. FDA and Korea's Ministry of Food and Drug Safety (MFDS).

"Myomics is a product that provides patients with cardiovascular diseases the opportunity to receive a quick diagnosis and timely treatment while increasing the convenience of medical staff, and we are pleased to contribute to the development of Taiwan's healthcare environment so that patients suffering from cardiovascular diseases can receive timely diagnosis and treatment," Phantomics CEO Kim Pan-ki said. "With the approval in Taiwan, we will further expand our overseas business in Asia, especially Greater China."